Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703534 · ClinicalTrials.gov registry record · Phase 2
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 478
- Enrollment target
NCT00703534: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00703534 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 478 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (259% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00703534, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 478 participants
- Enrollment target
Study Summary
This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
Primary Outcome
Symptom intensity rated on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe)
Interventions
- DRUG Placebo
- DRUG AZD3355
- DRUG Gelusil®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00703534 record still lists
NCT00703534 is an interventional study that assigns participants to a tested intervention. The registered 478 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (259% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00703534 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00703534 about?
NCT00703534 is a clinical study titled "Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms". This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).
What is the current status of trial NCT00703534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 478 participants. The study started on 2008-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00703534?
The interventions under investigation include: Placebo (DRUG), AZD3355 (DRUG), Gelusil® (DRUG).
Who is sponsoring clinical trial NCT00703534?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00703534's enrollment target sits among peer trials
478 77th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia